<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="uk">
		<id>http://istoriya.soippo.edu.ua/index.php?action=history&amp;feed=atom&amp;title=Erlotinib%3A_An_Quintessential_Relaxation%21</id>
		<title>Erlotinib: An Quintessential Relaxation! - Історія редагувань</title>
		<link rel="self" type="application/atom+xml" href="http://istoriya.soippo.edu.ua/index.php?action=history&amp;feed=atom&amp;title=Erlotinib%3A_An_Quintessential_Relaxation%21"/>
		<link rel="alternate" type="text/html" href="http://istoriya.soippo.edu.ua/index.php?title=Erlotinib:_An_Quintessential_Relaxation!&amp;action=history"/>
		<updated>2026-05-08T14:23:36Z</updated>
		<subtitle>Історія редагувань цієї сторінки в вікі</subtitle>
		<generator>MediaWiki 1.24.1</generator>

	<entry>
		<id>http://istoriya.soippo.edu.ua/index.php?title=Erlotinib:_An_Quintessential_Relaxation!&amp;diff=121502&amp;oldid=prev</id>
		<title>Drawer9parade: Створена сторінка: The age and sex distribution of the 113 subjects used for the type I analysis and the 56 subjects used for the type IIa analysis are depicted in Fig. 2A?and?B,...</title>
		<link rel="alternate" type="text/html" href="http://istoriya.soippo.edu.ua/index.php?title=Erlotinib:_An_Quintessential_Relaxation!&amp;diff=121502&amp;oldid=prev"/>
				<updated>2016-12-14T20:21:18Z</updated>
		
		<summary type="html">&lt;p&gt;Створена сторінка: The age and sex distribution of the 113 subjects used for the type I analysis and the 56 subjects used for the type IIa analysis are depicted in Fig. 2A?and?B,...&lt;/p&gt;
&lt;p&gt;&lt;b&gt;Нова сторінка&lt;/b&gt;&lt;/p&gt;&lt;div&gt;The age and sex distribution of the 113 subjects used for the type I analysis and the 56 subjects used for the type IIa analysis are depicted in Fig. 2A?and?B, respectively. As expected, the data demonstrated a bimodal distribution of ages with peaks in the 30�C39 and 70�C79 years old age groups. Table 1 contains descriptive statistics for?Po, diameter, depth, CSA and SF for the 1863 type I and 535 type IIa fibres that [http://www.selleckchem.com/products/Erlotinib-Hydrochloride.html buy Erlotinib] were analysed. These values are similar to those we have previously published. The size (diameter, depth and CSA) is larger for type I fibres, but SF is higher in type IIa fibres (P?[http://en.wikipedia.org/wiki/MCF2L MCF2L] type I fibres from an individual subject are depicted in Fig. 4; the slope in this particular example is 1.01. Histograms of the slopes from individually fitted least-squares lines for the log?Po?versus?log diameter plot of each subject are shown in Fig. 5A?and?B for type I and IIa fibres, respectively. For both fibre types, the mode falls between 0.75 and 1.25. Table 2 shows the results from the linear mixed effects model for the log�Clog slope in both type I and type IIa fibres. The slope estimate of log?Po?versus?log diameter for type I fibres is 0.99, which almost perfectly corresponds to a power law of?Po as proportional to diameter. The corresponding log�Clog slope for type IIa fibres is 0.94, also close to 1. Thus,?Po is proportional to diameter rather than CSA for both type I and type IIa fibres. If?Po were proportional to CSA, the slope estimate on the log�Clog scale would be approximately 2. We tested the hypothesis that?Po is proportional to diameter, i.e. the log�Clog slope is 1, as well as the hypothesis that?Po is proportional to diameter squared or CSA, i.e. that the log�Clog slope is 2. The first test accepts the null hypothesis of proportionality, i.e. that the slope is 1 on the log�Clog plot (P?= 0.78 for type I and?P?= 0.48 for type IIa fibres). The second test rejects the null hypothesis of a square law, i.e. that the slope relating log?Po to log diameter is 2 (P?[http://www.selleckchem.com/products/AP24534.html Ponatinib clinical trial] for type I and?P?&lt;/div&gt;</summary>
		<author><name>Drawer9parade</name></author>	</entry>

	</feed>